Premarin Vaginalconjugated estrogens

According to the FDA label: Premarin Intravenous (conjugated estrogens, USP) for injection is indicated in the treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology. Premarin Intravenous is indicated for short-term use only, to provide a rapid and temporary increase in estrogen levels.

57,798 adverse event reports submitted to the FDA (1996–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Premarin Vaginal in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Premarin Vaginal adverse event reports by reporter sex
SexReports
Female55,349
Male188
Unknown101

By Age Group

View age group data as a table
Premarin Vaginal adverse event reports by reporter age group
Age groupReports
0-17186
18-34342
35-492,752
50-6413,985
65-747,579
75+4,527

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Premarin Vaginal. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Premarin Vaginal adverse event reports by reported outcome
OutcomeReports
Other Serious35,959
Non-Serious16,459
Hospitalization9,256
Death1,779
Disability1,681
Life-Threatening757

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Premarin Vaginal. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Premarin Vaginal adverse event reports by year
YearReports
19961
19971
20011
20031
20044,079
20053,443
20063,128
20071,616
20083,551
20095,095
20109,076
20112,650
20122,529
20132,119
20142,025
20152,436
20162,521
20171,958
20181,752
20192,101
20202,254
20211,493
20221,369
20231,053
2024826
2025616
2026 (partial)104

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Premarin Vaginal

In FDA adverse event reports that mention Premarin Vaginal, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026